Fig. 1 · Structure

Documents & Downloads

BMH-21

Cat. No. A14335 CAS 896705-16-1

RNA polymerase inhibitor

BMH-21 is a potent small molecule DNA intercalator. BMH-21 binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.

In Stock

Publications for BMH-21

3 publications citing this product

  1. Kreeti Kajal, Elham Rastegari, .et al. , EMBO Reports, 2026, 27: 1870-1903 PMID: 41663759
  2. Jun Kumai, .et al. , Exp Cell Res, 2025, Jul 15;450(2):114629 PMID: 40466802
  3. Masahiko Okuda, .et al. , Nucleic Acids Res, 2021, Jul 16 PMID: 34268577

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

BMH-21 inhibits Pol I transcription elongation in reconstituted assays. Purified yeast Pol I showed delayed nucleotide addition and pausing, while Pol II was unaffected and Pol III was modestly inhibited under the tested conditions. BMH-21 did not measurably destabilize the isolated elongation complexes in a separate high-salt control assay. [1]

In A375 melanoma cells, BMH-21 induced loss of the Pol I catalytic subunit RPA194 after rapid inhibition of nascent RNA synthesis. Proteasome blockade reduced RPA194 loss without restoring rRNA transcription, indicating that the initial transcriptional inhibition can be separated from subsequent protein loss. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
RNA polymerase I

Cellular Effect

Cell Line Activity Value Description Reference
U2OS IC50 0.05 μM Induction of RNA polymerase-1 RPA194 subunit degradation in human U2OS cells after 3 hrs by epifluorescence microscopic analysis [PMID: 24847734]
U2OS IC50 0.07 μM Inhibition of RNA polymerase-1 in human U2OS cells assessed as decrease in nucleolar localization of nucleolin after 3 hrs by epifluorescence microscopic analysis [PMID: 24847734]

In Vitro Studies

The RPA194 response depends on the cellular model. BMH-21 reduced RPA194 in U2OS cells, whereas RPMI-7951 melanoma cells retained RPA194 despite nucleolar reorganization. WS-1 normal fibroblasts also retained RPA194 under the tested conditions. These results limit generalization of RPA194 degradation across cell types. [2]

Comparative transcription elongation by purified Pol I, II and III

Biochemical assay · Purified Saccharomyces cerevisiae RNA polymerases I, II and III on a defined RNA:DNA scaffold [1]

BMH-21 delayed Pol I nucleotide addition and produced persistent intermediates consistent with pausing. Pol II showed no detectable effect under the tested conditions, while Pol III was modestly inhibited.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Pol I versus Pol II/III elongation responseQualitative comparative response Pol I: slower nucleotide addition and persistent 11-/12-mer intermediates; Pol II: no observed inhibition; Pol III: modest inhibition[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM BMH-21 as reported for the preincubation and figure condition
Exposure duration
5 min preincubation; reaction time course 0.005–10 s
Method
Reconstituted multi-nucleotide addition; quenched-flow sampling and gel-resolved RNA intermediates
Vehicle
BMH-21 storage buffer: 0.1 M NaH2PO4, pH 6
Reported limits
Supplement not retrieved; final concentration after mixing not independently clarified beyond the main-text condition. Chemical form and lot characterization not specified in the read main-text methods.
Methods and source locations

Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21; salt/form unspecified

Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.

Methods 2.1–2.3; Results 3.1–3.3; Figures 1–4 and captions; Discussion 4.1

Pol I versus Pol II/III elongation response: Globally fitted multi-nucleotide addition time courses; three independent reactions per condition — Results 3.1–3.3; Figures 1–4; Methods 2.2–2.3

Elongation-complex stability control

Biochemical assay · Purified S. cerevisiae Pol I, II or III elongation complexes [1]

BMH-21 did not measurably accelerate elongation-complex collapse in the tested high-salt assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fraction of elongation-complex collapseQualitative negative result No detectable BMH-21-dependent destabilization of Pol I, II or III elongation complexes[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
Time course shown in Figure 5; no exact endpoint inferred from plot
Method
RNase protection assay of elongation-complex collapse with 1 M KCl and 10 μM RNase A
Vehicle
Storage-buffer vehicle (Methods 2.2)
Reported limits
Exact time schedule is not transcribed from the plotted axis; supplement not retrieved.
Methods and source locations

Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21; salt/form unspecified

Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.

Methods 2.4; Results 3.4; Figure 5A–C and caption

Fraction of elongation-complex collapse: RNase-sensitive 7-mer relative to total RNA; three independent reactions; plotted mean ± SD — Results 3.4; Figure 5A–C and caption; Methods 2.4

RPA194 loss and proteasome-blockade control in A375 cells

Cell-based study · Human A375 melanoma cells [2]

RPA194 loss followed rapid inhibition of nascent RNA synthesis. Proteasome inhibitors retained RPA194 but did not restore rRNA transcription, separating transcription arrest from protein loss.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RPA194 protein abundanceQualitative decrease RPA194 decreased following BMH-21 treatment; loss was reduced by proteasome blockade[2]
Nascent rRNA synthesis despite RPA194 retentionQualitative negative rescue MG132 did not rescue transcription inhibition by BMH-21[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM BMH-21
Exposure duration
3 h for the principal protein/proteasome-blockade comparison; kinetic experiments at the indicated earlier times
Method
Western blotting, immunofluorescence, cycloheximide chase, uridine labeling
Vehicle
Control conditions as labeled in Figures 5 and 7; vehicle identity for these selected panels is not specified in the read captions
Co-treatment
Mechanistic controls: MG132 10 μM or lactacystin 2 μM, 30 min pretreatment, then 3 h BMH-21; not an anticancer combination-efficacy study
Reported limits
Supplemental cell-culture details and cycloheximide concentration not retrieved; no missing details inferred.
Methods and source locations

Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21, chemical name specified in Experimental Procedures; no salt named

Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.

Results: BMH-21 Causes Loss of Pol I Catalytic Subunit RPA194; Inhibition of RPA194 Degradation does not Rescue Pol I Transcription; Figures 5A–C,E–H and 7A–D; Experimental Procedures

RPA194 protein abundance: Western blot and confocal microscopy; NCL/loading and untreated/inhibitor controls as shown — Figures 5A–C,G–H and 7A–B; corresponding Results and captions

Nascent rRNA synthesis despite RPA194 retention: 3H-uridine metabolic labeling and FUrd incorporation; Figure 7C–D controls — Figure 7C–D and caption; Results: Inhibition of RPA194 Degradation does not Rescue Pol I Transcription

Cell-dependent RPA194 response

Cell-based study · U2OS osteosarcoma, RPMI-7951 melanoma and WS-1 normal fibroblast cells [2]

RPA194 decreased in U2OS but remained resistant to loss in RPMI-7951; normal fibroblasts also showed no RPA194 loss under the tested conditions. RPMI-7951 nevertheless showed nucleolar reorganization.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RPA194 abundance and nucleolar localizationModel-dependent response U2OS: RPA194 loss; RPMI-7951 and WS-1: no detected RPA194 loss; RPMI-7951: nucleolar caps/NCL redistribution[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM BMH-21
Exposure duration
Blots: U2OS and RPMI-7951, 1 and 3 h; WS-1, 3 and 6 h. Microscopy: WS-1, 8 h; RPMI-7951, 6 h (Figure 6A–D)
Method
Western blotting and nucleolar immunofluorescence
Vehicle
Untreated controls shown; NCL loading control
Co-treatment
Actinomycin D 50 ng/ml comparator in Figure 6A–B; comparator rather than cotreatment
Reported limits
Replicate number for Figure 6A–D is not specified in the read caption; SI not retrieved.
Methods and source locations

Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21; no salt named

Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.

Results: Decrease in RPA194 Correlates with Loss of Cancer Cell Survival; Figure 6A–D and caption

RPA194 abundance and nucleolar localization: Western blot with NCL control; microscopy for RPMI-7951 — Figure 6A–D and caption; Results: Decrease in RPA194 Correlates with Loss of Cancer Cell Survival

In Vivo Studies

In adult female Drosophila, a three-day BMH-21 food-exposure experiment reduced nucleolar area relative to nuclear area in intestinal stem/progenitor cells. It also reduced elevated mitotic stem-cell counts after dWdr4 depletion, while control-fly mitotic counts were unchanged. The study explicitly reports AdooQ A14335; the nominal treatment-solution concentration was 5 μM, with no measured ingested dose. [3]

Nucleolar and mitotic responses in dWdr4-depleted flies

Animal study · Adult female Drosophila melanogaster with esg-ts-driven dwdr4 RNAi(P), compared with esg-ts-driven mcherry RNAi controls [3]

BMH-21 reduced the nucleolar-to-nuclear area ratio in both genotypes and reduced elevated mitotic ISC counts after dWdr4 depletion. Mitotic counts in control flies were unchanged.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fibrillarin-positive nucleolar area / DAPI-positive nuclear areaDirection of response Reduced in both control and dwdr4 RNAi flies[3]
PHH3-positive ISCs per midgutMann–Whitney U comparison dwdr4 RNAi: decrease, P = 0.0075; mcherry RNAi control: no significant change, P = 0.7601[3]

Conditions shared by the study groups

Route
Food exposure
Frequency
Fresh treated food daily
Treatment course
3 days, beginning with 3–4-day-old females
Vehicle
BMH-21 prepared from a DMSO stock; DMSO control solution 0.1%
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BMH-21 exposure in both genotypes
5 μM BMH-21 solution applied to food; not mg/kg or measured consumption
Genotype-matched DMSO: dwdr4 RNAi N = 17 midguts; mcherry RNAi N = 9. Treated groups: N = 18 and N = 10, respectively. Caption reports n = 111 ISC/EB cells.Nucleolar area ratio decreased in both genotypes; PHH3-positive counts decreased after dwdr4 RNAi but were unchanged in control RNAi.[3]
BMH-21 exposure in both genotypes
Model: Adult female Drosophila melanogaster with esg-ts-driven dwdr4 RNAi(P), compared with esg-ts-driven mcherry RNAi controls
Reported limits: No measured consumed dose, tissue concentration or mammalian efficacy inference.
Methods and source locations

Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21 (AdooQ Bioscience, A14335)

Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.

Results: dWdr4 regulates ribosome biogenesis in ISCs; Figure 4D,D′ and caption; Methods: BMH-21 treatment; Sampling, quantification, and statistical analyses

Fibrillarin-positive nucleolar area / DAPI-positive nuclear area: Confocal image quantification in small-nucleus GFP-positive ISC/EB cells; plotted mean ± SD; Mann–Whitney U test — Figure 4D,D′ left plot and caption; Sampling, quantification, and statistical analyses

PHH3-positive ISCs per midgut: Midgut PHH3 immunostaining; plotted mean ± SD; midgut counts distinguish biological from cell sampling — Figure 4D,D′ right plot and caption

BMH-21 exposure in both genotypes · Figure 4D,D′ and caption; Methods: BMH-21 treatment

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 896705-16-1
Applications RNA polymerase inhibitor
Formula C21H20N4O2
Molecular Weight 360.4
SMILES
CN(C)CCNC(=O)C1=CC=CN2C1=NC3=CC4=CC=CC=C4C=C3C2=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 4 mg/mL (11.1 mM)
Water Insoluble
Ethanol Warmed: 2 mg/mL (5.54 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Ruth Q. Jacobs, Kaila B. Fuller, Stephanie L. Cooper, et al. RNA Polymerase I Is Uniquely Vulnerable to the Small-Molecule Inhibitor BMH-21 Cancers (2022). PMID: 36428638 DOI: 10.3390/cancers14225544 Source material
  2. [2] Karita Peltonen, Laureen Colis, Hester Liu, et al. A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity Cancer Cell (2014). PMID: 24434211 DOI: 10.1016/j.ccr.2013.12.009 Source material
  3. [3] Kreeti Kajal, Elham Rastegari, Wen-Der Wang, et al. Wdr4 regulates ribosome biogenesis and intestinal homeostasis via let-7 EMBO Reports (2026). PMID: 41663759 DOI: 10.1038/s44319-026-00701-y Source material

Publications

3 publications citing this product

  1. Kreeti Kajal, Elham Rastegari, .et al. , EMBO Reports, 2026, 27: 1870-1903 PMID: 41663759
  2. Jun Kumai, .et al. , Exp Cell Res, 2025, Jul 15;450(2):114629 PMID: 40466802
  3. Masahiko Okuda, .et al. , Nucleic Acids Res, 2021, Jul 16 PMID: 34268577

Added to your cart

View Cart Checkout
Loading...